Previous 10 | Next 10 |
2023-07-10 10:03:22 ET Gainers: NanoString Technologies ( NSTG ) +23% . NeuroOne Medical Technologies Corporation ( NMTC ) +21% . Novavax ( NVAX ) +18% . Sientra ( SIEN ) +15% . Losers: Outset Medical ( OM ) -12% . PainRe...
NEW YORK, NY / ACCESSWIRE / July 7, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR). Investors who purchased Allarity securities are encouraged to obtain additional ...
2023-07-07 10:07:00 ET Gainers: Castle Biosciences ( CSTL ) +43% . CareDx ( CDNA ) +20% . COMPASS Pathways ( CMPS ) +9% . TG Therapeutics ( TGTX ) +9% . KalVista Pharmaceuticals ( KALV ) +8% . Losers: PainReform ( P...
2023-07-06 13:08:25 ET Gainers: EdtechX Holdings Acquisition ( EDTX ) +40% . Mullen Automotive ( MULN ) +35% . Genius Sports Limited ( GENI ) +21% . Incannex Healthcare Limited ( IXHL ) +19% . Sweetgreen ( SG ) +18% . urban-g...
2023-07-06 06:22:56 ET Allarity Therapeutics ( NASDAQ: ALLR ) prices public offering of 2.44M common shares and common warrants to purchase up to 2.44M common shares at an effective combined price of $4.50 per share and common warrant for aggregate gross proceeds of ~$11M. The...
BOSTON, MA (July 6, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized canc...
Allarity Therapeutics Inc (NASDAQ: ALLR) is one of today's top gainers. The company's shares are currently up 56.51% on the day to $9.86. Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnosti...
Boston , MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics for p...
2023-06-28 01:55:32 ET Clinical-stage pharmaceutical company, Allarity Therapeutics ( NASDAQ: ALLR ) clarifies the effective date of its contemplated reverse stock split. The company is clarifying that the reverse stock split will not be effected on June 27, 2023,...
Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnos...
News, Short Squeeze, Breakout and More Instantly...
Allarity Therapeutics Inc. Company Name:
ALLR Stock Symbol:
NASDAQ Market:
Allarity Therapeutics Inc. Website:
Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it received notice from the NASDAQ S...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 6.8% to $126.09 on volume of 414,790,976 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 18.7% to $0.265 on volume of 162,165,405 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 12.6%...
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer...